Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. Patients with relapsed chronic lymphocytic leukaemia (CLL) received either otlertuzumab (20 mg/kg) weekly by IV infusion for two 28-day cycles then every 14 days for four 28-day cycles and IV bendamustine (70 mg/m 2 ) on Days 1 and 2 of each cycle for up to six 28-day cycles or bendamustine alone. Thirty-two patients were treated with otlertuzumab and bendamustine and 33 with bendamustine alone. Overall response rate according to the International Workshop on Chronic Lymphocytic Leukaemia criteria was 69% in the otlertuzumab and bendamustine arm and 39% in the bendamustine alone arm (P = 0Á025). Median progression-free survival (PFS) was 15Á9 months in the otlertuzumab and bendamustine arm and 10Á2 months in the bendamustine alone arm (P = 0Á0192). There was a higher incidence of pyrexia (34% vs. 12%) and neutropenia (59% vs. 39%) with the combination but this did not result in a higher incidence of severe (grade 3/4) infections (13% vs. 27%). This combination significantly increased the response rate and prolonged the PFS over single agent bendamustine in patients with relapsed or refractory CLL.
Summary
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. Patients with relapsed chronic lymphocytic leukaemia (CLL) received either otlertuzumab (20 mg/kg) weekly by IV infusion for two 28-day cycles then every 14 days for four 28-day cycles and IV bendamustine (70 mg/m 2 ) on Days 1 and 2 of each cycle for up to six 28-day cycles or bendamustine alone. Thirty-two patients were treated with otlertuzumab and bendamustine and 33 with bendamustine alone. Overall response rate according to the International Workshop on Chronic Lymphocytic Leukaemia criteria was 69% in the otlertuzumab and bendamustine arm and 39% in the bendamustine alone arm (P = 0Á025). Median progression-free survival (PFS) was 15Á9 months in the otlertuzumab and bendamustine arm and 10Á2 months in the bendamustine alone arm (P = 0Á0192). There was a higher incidence of pyrexia (34% vs. 12%) and neutropenia (59% vs. 39%) with the combination but this did not result in a higher incidence of severe (grade 3/4) infections (13% vs. 27%). This combination significantly increased the response rate and prolonged the PFS over single agent bendamustine in patients with relapsed or refractory CLL.
Keywords: otlertuzumab, CLL, bendamustine. Significant advances have occurred in the treatment of chronic lymphocytic leukaemia (CLL) but, in general, most patients eventually relapse after first line therapy (Hallek et al, 2010; Burger et al, 2012; Fischer et al, 2012; Goede et al, 2014) . Bendamustine alone or in combination with rituximab has emerged as an effective treatment strategy for patients with CLL (Kath et al, 2001; Bremer, 2002; Bergmann et al, 2005; Fischer et al, 2011 Fischer et al, , 2012 . In studies of bendamustine monotherapy, depending on the patient population, salvage therapy has resulted in an overall response rate (ORR) between 40-93% and a complete response (CR) rate between 7-30% (Kath et al, 2001; Aivado et al, 2002; Bremer, 2002; Bergmann et al, 2005; Lissitchkov et al, 2006) . In a phase 1/2 trial conducted by the German CLL Study Group, single agent bendamustine in patients with relapsed/refractory CLL, produced an ORR of 56% and a CR rate of 12%; progression-free survival (PFS) and overall survival (OS) were not reported (Bergmann et al, 2005) . In another trial conducted by the German CLL Study Group, the combination of bendamustine and rituximab was evaluated in a single arm Phase 2 study of patients with relapsed/refractory CLL and produced an ORR of 59% with a CR rate of 9% and a PFS of 15 months with an OS of 34 months (Fischer et al, 2011) .
CD37 is a heavily glycosylated cell surface protein that is expressed constitutively at high levels on human B cells and transformed mature human leukaemic B cells (Campo et al, 1991; Belov et al, 2001; Barrena et al, 2005) . Reduced cell surface expression of CD20 on peripheral B-CLL cells compared to B cells from healthy donors is a well-known hallmark of B-CLL (Ginaldi et al, 1998; D'Arena et al, 2000; Rawstron et al, 2001) . While the expression of CD37 on CLL cells also appears lower than expression on normal B cells (Peters et al, 1994; Barrena et al, 2005; Rafiq et al, 2013) , CD37 represents a solid alternative target for CLL with a surface antigen density similar to or higher than that of CD20 (Peters et al, 1994; Press et al, 1994) . Anti-CD37 antibodies currently in Phase 1 development for treatment of B cell malignancies include the monoclonal antibody BI836826 for CLL and the anti-CD37 immunoconjugates 131 I-MB-1, IMGN529 and 177 Lu-tetulomab (Betalutin TM ) for non-Hodgkin lymphoma . Otlertuzumab (TRU-016) is a CD37-specific, single-chain, homodimeric therapeutic protein built on the ADAPTIR (modular protein technology) platform, consisting of antibody-derived, single-chain variable fragments linked to immunoglobulin (Ig) constant domains (Byrd et al, 2009) . Otlertuzumab binds to CD37 and, like monoclonal antibodies, employs the effector function of Fc-dependent cytotoxicity (FcDCC), also known as antibody-dependent cellular cytotoxicity (ADCC). Otlertuzumab does not induce complement activation. It does induce apoptosis directly via binding to the CD37 receptor, which results in upregulation of BIM (also termed BCL2L11), a pro-apoptotic protein (Lapalombella et al, 2012) . Because otlertuzumab delivers its signal via interaction with CD37 rather than CD20, this drug offers the possibility for therapeutic benefit when CD20 is shed, blocked or removed from the surface of the targeted B cells, a limitation that has been reported in CLL (Jilani et al, 2003; Kennedy et al, 2003; Gopal et al, 2008) . In preclinical models, treatment with otlertuzumab resulted in increased antitumour activity when combined with other therapeutic drugs used for B-cell malignancies (Baum et al, 2009; Algate et al, 2010; Smolewski et al, 2014) .
In vitro studies show additive activity of otlertuzumab with bendamustine (Algate et al, 2010) . These findings were extended to in vivo xenograft models, where otlertuzumab plus bendamustine resulted in a greater inhibition of tumour growth as compared to that attained with each individual drug (Algate et al, 2010) .
The first-in-human Phase 1 trial of otlertuzumab demonstrated single-agent clinical activity and appeared to be well tolerated in an advanced CLL patient population (Byrd et al, 2014) . Thus, we hypothesized that the addition of otlertuzumab to bendamustine could further improve the response in CLL patients. The Phase 1b portion of this study demonstrated that otlertuzumab in combination with bendamustine was well tolerated and showed a positive response in subjects with relapsed CLL (Awan et al, 2012) . The randomized Phase 2 study reported here evaluates the safety, pharmacokinetics and efficacy of otlertuzumab and bendamustine compared to bendamustine alone.
Patients, materials, methods
This research was approved by the relevant institutional review boards or ethics committees and all human participants gave written informed consent. This trial was registered at www.clinicaltrials.gov as NCT01188681. The objective of this study was to compare the efficacy and safety of otlertuzumab in combination with bendamustine to bendamustine alone in patients with relapsed CLL. In addition, this study investigated the pharmacokinetics and pharmacodynamics of otlertuzumab and the development of antibodies to otlertuzumab.
Eligibility criteria and study design
Previously treated patients ≥18 years of age with a diagnosis of CLL by the 2008 International Workshop on CLL Criteria (IWCLL) (Hallek et al, 2008) and with Rai stage I-II (intermediate risk) or III-IV (high risk) CLL (Rai et al, 2000) who had refractory or relapsed disease after 1-3 prior treatments were included. Patients were required to have the following: an Eastern Cooperative Oncology Group (ECOG) performance status ≤2; creatinine clearance (CrCl) >40 ml/min; serum creatinine, total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤2Á09 upper limit of normal (ULN); an absolute neutrophil count (ANC) ≥1Á2 9 10 9 /l; platelet count ≥75 9 10 9 /l; and no anti-cancer or investigational therapy within 30 days of treatment.
Patients were not eligible if they had received treatment with rituximab or other B-cell depleting agents within 30 days before first study drug dose or alemtuzumab within 12 weeks before first study drug dose; were refractory to fludarabine or other purine analogue therapy; discontinued prior bendamustine secondary to toxicities; or had major surgery within 30 days before first study drug dose.
Dosing and premedication
In the combination arm, otlertuzumab (20 mg/kg) was administered by intravenous (IV) infusion over 2-3 h over six 28-day cycles. Dosing was weekly for the first 2 cycles, then on Day 1 and 15 of the next 4 cycles. In both arms, bendamustine (70 mg/m 2 ) was dosed on Days 1 and 2 of every 28-day cycle for 6 cycles. The dose of bendamustine was reduced when the ANC had not recovered to >1 9 10 9 /l and platelet count had not recovered to >50 9 10 9 /l by 28 days after dosing. After the first delay, bendamustine was reduced to 50 mg/m 2 , at the second occurrence bendamustine was reduced to 30 mg/m 2 , at the third occurrence, bendamustine was discontinued and at the fourth occurrence otlertuzumab was discontinued. Otlertuzumab was supplied by Emergent BioSolutions (Seattle, WA, USA). Bendamustine was purchased commercially. Patients were to receive full supportive care, including transfusions of blood and blood products, antibiotics, antiemetics, growth factors, as appropriate. Growth factors were not to be used prophylactically in the first cycle.
Safety assessments
Toxicity was assessed at each evaluation according to the National Cancer Institutes (NCI) Common Terminology
Criteria for Adverse Events (CTCAE), version 4.03 (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quick-Reference_8.5x11.pdf).
Response assessments
Response was assessed monthly by the investigator on the basis of complete blood count (CBC); clinical assessment including measurement of lymph node size and spleen and liver size by physical examination; and evaluation of constitutional symptoms secondary to CLL. The primary endpoint, overall response to treatment, was assessed by the investigator 2 months after the end of treatment using the 2008 IWCLL criteria (Hallek et al, 2008) which included clinical assessment, CBC, computed tomography (CT) scan results, bone marrow and aspirate results, and duration of response. Response was also assessed per the 1996 NCI Working Group Criteria (Cheson et al, 1996) . Progression during the follow-up period was determined by clinical criteria and CBC. A CT scan was not required to confirm progression (Blum et al, 2007) .
Pharmacokinetic analyses
Serum samples for pharmacokinetic (PK) analysis were analysed by a qualified and sensitive enzyme-linked immunosorbent assay specifically developed for otlertuzumab using a monoclonal antibody specific for the CD37 binding domain of otlertuzumab. For terminal elimination half-life calculations, a minimum of 3 time points with detectable levels of otlertuzumab were required to be included in final PK parameter estimates. Based on this requirement, 6 patients treated with otlertuzumab and bendamustine were excluded from mean parameter estimates. Actual times after otlertuzumab dose administration for individual subjects were used in all PK calculations; however, the proscribed times were used for graphing. Patients not receiving a full dose of otlertuzumab were excluded from PK parameter calculations, such as mean C max and total area under the concentration curve (AUC). Values for C max and time to reach C max (T max ) were obtained by direct inspection of data. Area under the concentrationtime curve (AUC t ) was determined by the log-linear trapezoidal rule from time 0 to the last observed concentration (C t ) at time t using GraphPad Prism â Version 6.01 (GraphPad Software, San Diego, CA, USA). Otlertuzumab PK parameters were estimated using validated WinNonlin Professional Version 6.3 software (Pharsight Corporation, Mountain View, CA, USA) with non-compartmental methods when a patient had sufficient late time points available for PK analysis. Individual concentration-time profiles were plotted and the terminal disposition rate constant (k z ) was determined by the log-linear regression of at least 3 points judged to be in the terminal phase. Descriptive statistics, such as means, standard deviations and precision [coefficient of variation (CV %)] were calculated for variables using Microsoft 
Statistical methods
An adaptive (minimization) randomization procedure was used to assign the patients at a 1:1 ratio to either otlertuzumab and bendamustine or bendamustine alone. The stratification factors in decreasing order of importance were:
1 High risk genomic features (del[17p13Á1] or TP53 mutation): yes or no 2 Cumulative Illness Rating Scale >6 or ≤6 3 CrCl <60 ml/min or ≥60 ml/min.
Randomization was conducted using a centralized Interactive Response Technology on a competitive basis for patient enrolment across all study sites.
The primary endpoint was the investigator-assessed ORR for otlertuzumab plus bendamustine and bendamustine alone. The primary efficacy analysis was to compare the combination of otlertuzumab and bendamustine to bendamustine alone with respect to the ORR [patients with partial response (PR) or CR]. Patients whose disease response could not be assessed were considered non-responders. Assuming an ORR of 58% with bendamustine and an ORR of 80Á7% with the combination of otlertuzumab and bendamustine (equivalent to a 39% improvement over 58%) it was assumed that a sample size of 60 evaluable patients would yield 80% power to show the combination has a significantly higher ORR than bendamustine alone at a onesided significance level of 20%. Secondary endpoints were CR rate, PFS and OS.
Data analyses were based on descriptive statistics. For continuous variables, these statistics included the following: mean, median, standard deviation, minimum and maximum. Final study analyses were conducted after the last patient stopped study treatment and response was assessed using intent-to-treat analysis. Time-to-event variables were described using Kaplan-Meier estimates, as well as mean and median time with 2-sided 80% confidence intervals of the mean and median (Ellis et al, 2008) .
Results

Patient characteristics and treatment
Sixty-seven patients were enrolled and 65 were treated at 20 sites between December 2011 and April 2013. One patient randomized to the combination arm had bladder cancer and was not treated and one patient randomized to the control arm (i.e., treatment with bendamustine alone) withdrew consent before beginning treatment. Baseline characteristics are summarized in Table I and prior therapies are summarized in Table II . Treatment arms were generally well balanced; however, patients in the combination arm were older, had more prior regimens, longer time since first diagnosis, and more bulky disease. More patients in the control arm were Rai Stage III or IV (36Á4%) compared to the combination arm (28Á1%). Two patients in the combination arm and 5 in the control arm had 17p13 deletions and 4 patients in the combination arm and 6 in the control arm had TP53 mutation. Five patients in the combination arm and 3 in the control arm were refractory to prior treatment, defined as relapse within 6 months after prior treatment. In all but one of these patients, a patient in the control arm, prior treatment included rituximab. One patient in each arm was refractory to bendamustine.
The median number of cycles received was 6 for each cohort (range 1-6 in the combination arm and 2-6 in the control arm). Exposure to otlertuzumab and bendamustine is summarized in Table III . Bendamustine exposure was similar between treatment arms. Median treatment duration for otlertuzumab was 156 days for the combination arm (range 2-193). Median treatment duration for bendamustine was 143 days in both arms. Seven patients (22%) in the combination arm and 12 patients (36%) in the control arm discontinued study treatment before completing all 6 cycles (Table IV) . Three patients (9%) in the combination arm and 7 patients (21%) in the control arm discontinued study treatment due to adverse events (Table V) . In the combination arm, 3 patients (9%) discontinued treatment due to disease progression and one withdrew to have a stem cell transplant. In the control arm, 3 patients (9%) discontinued treatment due to disease progression, one patient withdrew for an unspecified reason, and one patient withdrew consent. One patient in the control arm died during treatment due to acute heart failure.
Clinical responses
As shown in Table VI , ORR per IWCLL criteria was higher in the combination arm compared to the control arm (69% vs. 39%, P = 0Á026). Response rate per the NCI Working Group criteria were 81% in the combination arm compared to 67% in the control arm. Per the IWCLL criteria, in the combination arm, 3 patients (9%) had a CR, 1 patient had CR with incomplete marrow recovery, and 19 (59%) had PR. In the control arm, 1 patient (3%) had a CR and 12 (36%) had PR. Overall response rate by baseline characteristic is illustrated in Fig 1 and summarized by 17p deletions and TP53 mutations in Table VII . Min, minimum; Max, maximum; SD, standard deviation. *Number of total otlertuzumab infusions received = Total number of otlertuzumab infusion across all treatment cycles. †Average otlertuzumab dose received per infusion = otlertuzumab dose received per infusion summed across all treatment cycles/number of total otlertuzumab infusions received. §Total treatment duration = End date of the last otlertuzumab infusion -beginning date of first otlertuzumab infusion. All values are given as n (%). Median PFS was longer in the combination arm compared to the control arm (15Á9 months vs. 10Á2 months, P = 0Á0192, Fig 2A) . Median OS was not reached in either arm (Fig 2B) . After 2 years of follow-up, no deaths had occurred in the combination arm and 3 deaths had occurred in the control arm.
Toxicities
Adverse events are summarized in Table VIII. The overall incidence of adverse events was generally similar between treatment arms with 91% of patients in the combination arm and 100% in the control arm reporting an adverse event.
Severe neutropenia occurred more frequently in the combination arm compared to the control arm (56% vs. 39%), as did severe thrombocytopenia (19% vs. 15%). There were fewer grade 3/4 infections in the combination arm compared to the control arm (13% vs. 27%). No patients in the combination arm and two patients in the control arm had febrile neutropenia. Serious adverse events were less frequent in the combination arm compared to the control arm (31% vs. 45%). 
Pharmacokinetics and pharmacodynamics
Mean otlertuzumab concentration over time is shown in Fig 3. Mean PK parameter estimates are shown in Table IX .
The half-life of otlertuzumab ranged from 5 to 13 days, with a mean of 10 days. Average C max for patients dosed with 20 mg/kg otlertuzumab was approximately 1058 lg/ml. Average clearance and volume of distribution for otlertuzumab were 2Á17 ml/day/kg and 28Á8 ml/kg, respectively. The treatment schedule used for CLL patients maintained concentrations of otlertuzumab, with trough levels generally above 100 lg/ml. PK parameters were generally similar for males and females. The combination of otlertuzumab and bendamustine was more effective than bendamustine alone at reducing the malignant clone (Wilcoxon exact test, P < 0Á0001 ; Fig 4) . In the combination arm, the number of CD19+CD5+ cells was reduced, from a median of 28Á464 9 10 9 /l to 0Á0039 9 10 9 /l, at the end of treatment compared to a reduction, from 28Á867 9 10 9 /l to 0Á453 9 10 9 /l, in the control arm.
Discussion
This multicentre Phase 2 study in patients with relapsed/refractory CLL demonstrates that otlertuzumab in combination with bendamustine results in a significantly higher response rate as measured by standard response criteria and PFS without additional toxicity that may be expected from a combination therapy. Although the numbers are small and imbalanced between treatment arms (Table VII) , it is notable that the combination had some activity in patients with TP53 mutations (2/4 patients) although no patients with 17p deletions (0/2) had a response. Stratification took into account several factors so overall the randomization was balanced, although some individual components were not be balanced due to the small sample size of 65. Otlertuzumab in combination with bendamustine was well tolerated; 78% of patients were able to receive all 6 cycles of therapy and the rate of discontinuation due to adverse events was actually lower than in the control arm (9% vs. 21%). This difference is driven by a higher occurrence of CLL-related disease events in the control arm, which is consistent with the fact that the combination was more effective at reducing the malignant clone (Fig 4) . The overall incidence of adverse events and severe and serious adverse events were generally similar between the treatments. Although there was a greater incidence of severe neutropenia with the combination, there was not a greater incidence of severe or serious adverse events, including infections, in the otlertuzumab plus bendamustine arm compared to the bendamustine arm. The addition of bendamustine did not have a major impact on the half-life of otlertuzumab. In this combination study, the mean half-life was 10 days; in a single-agent study the mean half-life was 8-9 days (Byrd et al, 2014) .
The ORR for single agent bendamustine in relapsed CLL ranges from 40% to 93% with a CR rate of 7-30% (Kath et al, 2001; Aivado et al, 2002; Bremer, 2002; Bergmann et al, 2005; Lissitchkov et al, 2006; Niederle et al, 2013) . These studies (Table X) are confounded by the utilization of various doses of bendamustine, ranging from 50 to 100 mg/m 2 .
The patient populations also varied significantly between the studies with a median of 1-5 prior treatments; one study (Kath et al, 2001 ) is confounded by the inclusion of some treatment-na€ ıve patients and another study (Lissitchkov et al, 2006) by the inclusion of fludarabine-na€ ıve patients. Response in these published studies with bendamustine was assessed using the 1996 NCI Working Group guidelines for CLL. The IWCLL criteria are more rigorous than the NCI Working Group criteria in that it requires CT scans and that the subject has been off study drug for at least 2 months for the assessment of a CR. This is reflected in the IWCLL response rate demonstrated in the control arm of our study of 39%, which is a lower response rate than reported from the historic literature. If one uses the NCI Working Group criteria, the overall response rate in the control arm is 67%. Additionally, the previous single agent studies with bendamustine were uncontrolled with small sample sizes (15-49). Hence, response rates for bendamustine from these single-arm small trials is wide and cannot be generalized. Bendamustine was used as the control for this study, because at the time the study was designed there was no randomized controlled data supporting the superiority of the combination of bendamustine and rituximab over bendamustine alone. Bendamustine has been used in combination with rituximab, a B-cell depleting agent for the treatment of CLL. In a combination trial with rituximab in front-line CLL (n = 117), the ORR was 88% with a CR rate of 23% and a PFS of 34 months (Fischer et al, 2012) . The same combination was used in relapsed CLL and the ORR was 59% with a CR rate of 9% and a PFS of 15 months (Fischer et al, 2011) . In the single agent study of bendamustine in relapsed CLL the ORR was 56% with a CR rate of 12% (Bergmann et al, 2005) . These studies both used the older 1996 NCI Working Group criteria for response and none used a control group. These single arm studies suggested that the ORR with bendamustine and rituximab was similar to responses reported for bendamustine alone.
The strength of the current study is that it was a randomized, stratified and controlled study, and utilized the newer IWCLL 2008 response criteria (Hallek et al, 2008) . Otlertuzumab adds to the efficacy of bendamustine without increasing toxicity. The favourable safety profile suggests that otlertuzumab may be a good partner for novel substances such as ibrutinib, venetoclax or idelalisib. The mechanism of action of otlertuzumab suggests synergy between otlertuzumab and idelalisib and this has been supported by preclinical work (Lapalombella et al, 2012) . Other preclinical studies show an additive effect of otlertuzumab with mTOR inhibitors (Algate et al, 2010) , CD20 antibodies, PI3K inhibitors and ibrutinib (McMahan et al, 2014) . Otlertuzumab is currently being studied in an ongoing clinical trial in combination with rituximab, obinutuzumab or ibrutinib and in combination with rituximab and idelalisib (NCT01644253). The place for otlertuzumab has yet to be defined in the rapidly evolving field of CLL and this will require additional studies in combination with the newer agents. The activity, safety profile and combinatorial activity of otlertuzumab with a wide range of drugs holds the promise that it may become a useful drug in the treatment armamentarium for CLL. 
